Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
HMGA1 encodes a non-histone protein involved in many cellular processes, including regulation of inducible gene transcription, integration of retroviruses into chromosomes, and the metastatic progression of cancer cells. Additionally we are shipping High Mobility Group AT-Hook 1 Proteins (20) and High Mobility Group AT-Hook 1 Kits (12) and many more products for this protein.
Showing 10 out of 121 products:
Human Polyclonal HMGA1 Primary Antibody for IHC, ELISA - ABIN185443
Chiappetta, Botti, Monaco, Pasquinelli, Pentimalli, Di Bonito, DAiuto, Fedele, Iuliano, Palmieri, Pierantoni, Giancotti, Fusco: HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. in Clinical cancer research : an official journal of the American Association for Cancer Research 2004
Show all 2 references for ABIN185443
Human Polyclonal HMGA1 Primary Antibody for FACS, IF - ABIN653050
Mu, Liu, Zhou, Xu, Jiang, Wang, Qu: Correlation of overexpression of HMGA1 and HMGA2 with poor tumor differentiation, invasion, and proliferation associated with let-7 down-regulation in retinoblastomas. in Human pathology 2010
Show all 2 references for ABIN653050
Human Polyclonal HMGA1 Primary Antibody for EIA, FACS - ABIN952761
Kim, Lee, Park, Kim, Lee, Cho, Shin, Cho, Lee, Han, Yoo, Lee: Identification of 15 loci influencing height in a Korean population. in Journal of human genetics 2010
Show all 2 references for ABIN952761
Cow (Bovine) Polyclonal HMGA1 Primary Antibody for EIA, WB - ABIN401518
Liau, Rocha, Matros, Redston, Whang: High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. in Cancer 2008
Taken together, our data demonstrate that miR (show MLXIP Antibodies)-625 suppresses cell proliferation and migration by targeting HMGA1 and suggest miR (show MLXIP Antibodies)-625 as a promising prognostic biomarker and a potential therapeutic target for breast cancer.
Inactivation of the Cdkn2a (show CDKN2A Antibodies) locus cooperates with HMGA1 to drive T-cell leukemogenesis.
Increased HMGA1 expression is associated with pituitary and thyroid tumors.
activated HMGA1 regulates cell proliferation through the Notch1 (show NOTCH1 Antibodies) signaling pathway, which represents an important molecular pathway leading to leukemogenesis.
Data propose that, by affecting the expression of both IGFBP protein species, HMGA1 can serve as a modulator of IGF-I (show IGF1 Antibodies) activity, thus representing an important novel mediator of glucose disposal.
HMGA1 contributes to the neurogenic potential of neural precursor cells in the early stages of neocortical development.
Elevated expression of HMGA1 is associated with the transition of prostate cancer (PCa (show ENPP1 Antibodies)) cells from androgen-sensitive to androgen-independent growth and plays a role in the cell growth of androgen-independent PCa (show ENPP1 Antibodies) cells.
The data in the present study reveal a role of Hmga1 in transcriptional silencing in T cell lineages and leukemic cells.
High-mobility group (show SSRP1 Antibodies) A1 protein is a new coregulator of peroxisome proliferator-activated receptor-gamma (show PPARG Antibodies)-mediated transrepression in the vasculature.
Basal and cyclic AMP (show TMPRSS5 Antibodies)-induced Rbp4 (show RBP4 Antibodies) transcription is regulated by a multiprotein complex that is similar to ones that modulate expression of genes of steroid hormone biosynthesis.
In breast cancer patients, high levels of HMGA1 and CCNE2 (show CCNE2 Antibodies) expression are associated with the YAP (show YAP1 Antibodies)/TAZ (show TAZ Antibodies) signature.
HMGA1 is overexpressed in human breast carcinomas and its levels are associated with a particular endocrine status.
Report epigenetic modification of miRNA targets HMGA (show HGD Antibodies) transcripts on pituitary cells.
Our data indicates that measuring urine high mobility group AT-hook 1 may serve as a useful diagnostic tool for serous epithelial ovarian cancer.
The HMGA1 rs146052672 genotype variant had an overall statistically significant effect on increasing the risk of development of type 2 diabetes mellitus in Europeans. (Meta-analysis)
Results show that HMGA1 binds CRMP1 (show CRMP1 Antibodies) promoter and regulates its expression in medulloblastoma cells.
HMGA1 plays an important role on breast cancer aggressiveness and prognosis and may act as a promising target for prognostic prediction.
CBX7 (show CBX7 Antibodies)/HMGA1b/NF-kappaB (show NFKB1 Antibodies) could take part in the same transcriptional mechanism that finally leads to the regulation of SPP1 (show SPP1 Antibodies) gene expression in papillary thyroid carcinoma.
The results of the present study indicate that miR (show MLXIP Antibodies)-26a may be associated with human breast carcinogenesis, which inhibits tumor cell proliferation by targeting HMGA1.
High expression of HMGA1 along with miR (show MLXIP Antibodies)-26a downregulation indicated a worse prognosis for patients with urothelial bladder cancer.
distinct loci exist for growth and fatness in the two populations and identified HMGA1 and PLAG1 (show PLAG1 Antibodies) as strong candidate genes on SSC7 and SSC4, respectively.
Characterization of polymorphisms in the HMGA1 gene in relation to growth and fat deposition.
This gene encodes a non-histone protein involved in many cellular processes, including regulation of inducible gene transcription, integration of retroviruses into chromosomes, and the metastatic progression of cancer cells. The encoded protein preferentially binds to the minor groove of A+T-rich regions in double-stranded DNA. It has little secondary structure in solution but assumes distinct conformations when bound to substrates such as DNA or other proteins. The encoded protein is frequently acetylated and is found in the nucleus. At least seven transcript variants encoding two different isoforms have been found for this gene.
high mobility group protein HMG-I/HMG-Y
, high mobility group protein A1
, high mobility group AT-hook protein 1
, high mobility group AT-hook 1
, high-mobility group (nonhistone chromosomal) protein isoforms I and Y
, high mobility group protein R
, nonhistone chromosomal high-mobility group protein HMG-I/HMG-Y
, high mobility group HMGA1A
, high mobility group HMGA1B
, non-histone protein
, high-mobility group AT-hook 1
, high mobility group protein I
, High mobility group AT-hook protein 1
, High mobility group protein A1
, high mobility group-I protein